The role of PRC2 in leukemia has been studied (Carlo et al., 2019), and in particular, the catalytic PRC2 core component EZH2 has been reported to be overexpressed in CML (Xie et al., 2016). This evidence concerns the gene EZH2 and chronic myelogenous leukemia, BCR-ABL1 positive.